Biohaven’s lead clinical asset ... topline results from its pivotal Phase 3 study which demonstrated that Troriluzole dosed at 200mg daily slowed disease progression of 50-70%, which the ...

Based on FDA Priority Review timelines and, if ultimately approved, Biohaven is prepared to commercialize troriluzole for SCA in the US in 2025. The Company had previously achieved positive ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed” data ...

Troriluzole 200 mg dosed orally ... BHV-1300 and BHV-1310 are IgG degraders; Biohaven introduced next generation TRAPTM (Targeted Removal of Aberrant Protein) degraders, which are highly selective ...

Biohaven has a one year low of $26.80 and ... The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric ...

Biohaven has a 1 year low of $26.80 and a ... The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric ...